Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain EBS message board posts where the ticker symbol EBS has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest EBS SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-17-045556 Size: 4 KB
2017-12-11
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-17-010405 (34 Act)  Size: 10 KB
2017-12-07 001-33137
171243594
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-027619 Size: 17 KB
2017-11-30
4/A  Documents [Amend] Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-026845 Size: 17 KB
2017-11-17
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-026353 Size: 9 KB
2017-11-15
8-K  Documents Current report, items 3.02, 8.01, and 9.01
Acc-no: 0001367644-17-000051 (34 Act)  Size: 51 KB
2017-11-14 001-33137
171203124
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-17-042137 Size: 6 KB
2017-11-13
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-17-041866 Size: 13 KB
2017-11-09
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-17-041378 Size: 15 KB
2017-11-07
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001367644-17-000048 (34 Act)  Size: 4 MB
2017-11-03 001-33137
171175416
More EBS SEC Filings


Related news from
Sat, 09 Dec 2017
17:00:00 +0000
Six Off the Beaten Path Healthcare Stock Gems
These lesser-known diagnostic and life sciences firms are involved in areas from genetic tools to telemedicine.
Fri, 08 Dec 2017
16:51:04 +0000
Vertex Kalydeco Study Successful in Children Aged 1-2 Years
Vertex Pharmaceuticals' (VRTX) phase III study evaluating Kalydeco in children as young as one year meets its primary safety endpoint.
Fri, 01 Dec 2017
14:12:02 +0000
New Strong Buy Stocks for December 1st
New Strong Buy Stocks for December 1st
Fri, 01 Dec 2017
13:05:41 +0000
See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
Emergent Biosolutions Inc NYSE:EBS
Thu, 30 Nov 2017
12:47:15 +0000
Treichl Sees Central Banks Taking Over Bitcoin
Nov.30 -- Andreas Treichl, chairman and chief executive officer at Erste Group Bank, discusses bitcoin and why he says central banks will not allow the cryptocurrency to happen. He speaks with Guy Johnson on “Bloomberg Markets: European Open.”
Thu, 30 Nov 2017
12:00:00 +0000
Emergent BioSolutions to Host 2017 Analyst & Investor Day
GAITHERSBURG, Md., Nov. 30, 2017-- Emergent BioSolutions Inc. today announced that the company will host an analyst and investor day on December 7, 2017 in New York City.. This event, which is designed ...
Tue, 28 Nov 2017
11:37:11 +0000
New Strong Buy Stocks for November 28th
New Strong Buy Stocks for November 28th
Fri, 24 Nov 2017
21:55:16 +0000
Should You Buy Emergent BioSolutions Inc (EBS) At This PE Ratio?
Emergent BioSolutions Inc (NYSE:EBS) is currently trading at a trailing P/E of 20.6x, which is lower than the industry average of 26.9x. While EBS might seem like an attractive stockRead More...
Thu, 23 Nov 2017
12:16:34 +0000
Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : November 23, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Emergent BioSolutions, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more <b>(Read more...)</b>
Mon, 20 Nov 2017
12:00:00 +0000
Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility
GAITHERSBURG, Md., Nov. 20, 2017-- Emergent BioSolutions Inc. today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the manufacture ...
Tue, 14 Nov 2017
22:38:02 +0000
Emergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Senior Notes Due 2021
GAITHERSBURG, Md., Nov. 14, 2017-- Emergent BioSolutions Inc. announced today that it has issued a Notice of Termination of Conversion Rights for all of its outstanding 2.875% Convertible Senior Notes ...
Thu, 09 Nov 2017
17:39:05 +0000
Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up
Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The company ups its guidance, courtesy of a continued positive execution across all business segments.
Wed, 08 Nov 2017
22:59:50 +0000
ETFs with exposure to Emergent BioSolutions, Inc. : November 8, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Emergent BioSolutions, Inc. Here are 5 ETFs with the largest exposure to EBS-US. Comparing the performance and risk of Emergent BioSolutions, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more <b>(Read more...)</b>
Wed, 08 Nov 2017
19:48:00 +0000
New Contracts and Products Help Emergent BioSolutions Inc Get It Done
The bioterrorism specialist posts a solid third quarter as it moves towards $1 billion in revenue in 2020.
Wed, 08 Nov 2017
17:21:05 +0000
Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut
Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.
Wed, 08 Nov 2017
14:53:02 +0000
Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat
Arena Pharmaceuticals (ARNA) reports another quarter of lackluster Belviq sales. However, the company is likely to advance ralinepag in phase III study based on positive data from the previous stage.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "VF is the place to be to pick up on new and proven investment ideas." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards